CTAD Notebook: Novo’s Semaglutide Data Show No Difference From Placebo In AD

EVOKE/EVOKE+ Revealed Similar Rates Of Cognitive Decline

 
• By Mandy Jackson
  
More detailed data for semaglutide in Alzheimer's disease will be presented next year (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Scrip